Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILIA: tozorakimab in hospitalized patients with viral lung infection requiring supplemental oxygen
2022-003107-15Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in viral pneumonia comparing Tozorakimab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Proportion of participants who die or progress to IMV/ECMO. Started Oct 2022; status: active.
02
Drugs
tozorakimab
03
Conditions
viral pneumonia
Beyond the preview
Go deeper on 2022-003107-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003107-15.